Seres Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Seres Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2012 to Q4 2023.
  • Seres Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $313M, a 12.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $313M +$35.4M +12.8% Dec 31, 2023 8-K 2024-08-15
Q4 2022 $277M +$57.3M +26% Dec 31, 2022 8-K 2024-08-15
Q4 2021 $220M +$26.4M +13.6% Dec 31, 2021 8-K 2024-08-15
Q4 2020 $194M +$36.4M +23.1% Dec 31, 2020 10-K 2024-03-05
Q4 2019 $157M +$25.3M +19.2% Dec 31, 2019 10-K 2023-03-07
Q4 2018 $132M +$37.9M +40.2% Dec 31, 2018 10-K 2022-03-01
Q4 2017 $94.1M +$11.1M +13.4% Dec 31, 2017 10-K 2021-03-02
Q4 2016 $83M +$50.2M +153% Dec 31, 2016 10-K 2020-03-02
Q4 2015 $32.8M +$22.3M +212% Dec 31, 2015 10-K 2019-03-06
Q4 2014 $10.5M +$6.23M +145% Dec 31, 2014 10-K 2018-03-08
Q4 2013 $4.29M +$2.7M +169% Dec 31, 2013 10-K 2017-03-16
Q4 2012 $1.6M Dec 31, 2012 10-K 2016-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.